Answer
Itovebi with palbociclib/fulvestrant treats adults’ PIK3CA-mutated, ER-positive, HER2-negative locally advanced/metastatic breast cancer recurring during/within 12 months after adjuvant endocrine therapy; prior (neo)adjuvant CDK4/6 treatment requires ≥12 months from cessation to recurrence, and pre/perimenopausal women and men require an LHRH agonist.
Sources for this answer
- Itovebi 3 mg & 9mg film-coated tabletsRoche Products Limited · emc · SmPC §4.1 Therapeutic Indications · Version 3Document updated
Sources checked